{"id":240800,"date":"2026-09-10T12:38:01","date_gmt":"2026-09-10T07:08:01","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=240800"},"modified":"2026-09-10T12:38:01","modified_gmt":"2026-09-10T07:08:01","slug":"multibagger-healthcare-stock-rises-550-percent-in-1-year","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/multibagger-healthcare-stock-rises-550-percent-in-1-year\/","title":{"rendered":"This Multibagger Healthcare Stock Rises 550% in 1 Year: What Is Behind the Surge?"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Cupid CMP approximately Rs 281 (10 Sep 2026). 1-year return 550.05%. 52W range Rs 37.46 to Rs 299. Market cap Rs 37,597 Cr. Q1 FY27 PAT Rs 44 Cr vs Rs 15 Cr.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">Cupid Ltd, a condom and sexual wellness products maker, is the multibagger healthcare stock that returned approximately 550% in one year. The gain is real, bonus-adjusted appreciation driven by profits that nearly tripled, repeated guidance upgrades and new capacity. At a PE near 274, the valuation leaves little room for disappointment.<\/p>\n<\/div>\n<p>This multibagger healthcare stock has turned Rs 1 lakh into roughly Rs 6.5 lakh in just one year. A sexual wellness and contraceptive manufacturer ranked second among 101 NSE stocks in our screen with a 1-year return of 550.05%, as of 10 September 2026.<\/p>\n<p>The company is <a href='https:\/\/univest.in\/stocks\/cupid\/cupid-ltd-share-price-today'>Cupid Ltd<\/a> (NSE: CUPID), a Nashik-based maker of male and female condoms, lubricants and diagnostic kits that now also sells perfumes, deodorants and personal care products. The Cupid share price traded around Rs 281.40 on 10 September 2026, up about 0.6% on the day, giving the company a market value of approximately Rs 37,597 crore.<\/p>\n<p style=\"margin-top:24px;\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/multibagger-healthcare-stock-rises-550-percent-in-1-year\/#Which_Multibagger_Healthcare_Stock_Rose_550_in_1_Year\" title=\"Which Multibagger Healthcare Stock Rose 550% in 1 Year?\">Which Multibagger Healthcare Stock Rose 550% in 1 Year?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/multibagger-healthcare-stock-rises-550-percent-in-1-year\/#Is_the_550_Rise_Real_or_a_Bonus_Share_Effect\" title=\"Is the 550% Rise Real or a Bonus Share Effect?\">Is the 550% Rise Real or a Bonus Share Effect?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/multibagger-healthcare-stock-rises-550-percent-in-1-year\/#Why_Did_This_Multibagger_Healthcare_Stock_Rise_550\" title=\"Why Did This Multibagger Healthcare Stock Rise 550%?\">Why Did This Multibagger Healthcare Stock Rise 550%?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/multibagger-healthcare-stock-rises-550-percent-in-1-year\/#1_Profits_Nearly_Tripled_in_a_Year\" title=\"1. Profits Nearly Tripled in a Year\">1. Profits Nearly Tripled in a Year<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/multibagger-healthcare-stock-rises-550-percent-in-1-year\/#2_Guidance_Raised_Again_and_Again\" title=\"2. Guidance Raised Again and Again\">2. Guidance Raised Again and Again<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/multibagger-healthcare-stock-rises-550-percent-in-1-year\/#3_Global_Tender_Wins_and_Export_Price_Hikes\" title=\"3. Global Tender Wins and Export Price Hikes\">3. Global Tender Wins and Export Price Hikes<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/multibagger-healthcare-stock-rises-550-percent-in-1-year\/#4_New_Capacity_and_a_Consumer_Products_Push\" title=\"4. New Capacity and a Consumer Products Push\">4. New Capacity and a Consumer Products Push<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/multibagger-healthcare-stock-rises-550-percent-in-1-year\/#How_Does_This_Multibagger_Healthcare_Stock_Compare_With_Its_Sector\" title=\"How Does This Multibagger Healthcare Stock Compare With Its Sector?\">How Does This Multibagger Healthcare Stock Compare With Its Sector?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/multibagger-healthcare-stock-rises-550-percent-in-1-year\/#Financial_Performance_of_the_Multibagger_Healthcare_Stock\" title=\"Financial Performance of the Multibagger Healthcare Stock\">Financial Performance of the Multibagger Healthcare Stock<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/multibagger-healthcare-stock-rises-550-percent-in-1-year\/#Who_Owns_This_Multibagger_Healthcare_Stock\" title=\"Who Owns This Multibagger Healthcare Stock?\">Who Owns This Multibagger Healthcare Stock?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/multibagger-healthcare-stock-rises-550-percent-in-1-year\/#Key_Risks_Before_Buying_This_Multibagger_Healthcare_Stock\" title=\"Key Risks Before Buying This Multibagger Healthcare Stock\">Key Risks Before Buying This Multibagger Healthcare Stock<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/multibagger-healthcare-stock-rises-550-percent-in-1-year\/#Cupid_Share_Analyst_View\" title=\"Cupid Share: Analyst View\">Cupid Share: Analyst View<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/multibagger-healthcare-stock-rises-550-percent-in-1-year\/#Cupid_Share_Price_Target\" title=\"Cupid Share Price Target\">Cupid Share Price Target<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/multibagger-healthcare-stock-rises-550-percent-in-1-year\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/multibagger-healthcare-stock-rises-550-percent-in-1-year\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/multibagger-healthcare-stock-rises-550-percent-in-1-year\/#Which_multibagger_healthcare_stock_rose_550_in_1_year\" title=\"Which multibagger healthcare stock rose 550% in 1 year?\">Which multibagger healthcare stock rose 550% in 1 year?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/multibagger-healthcare-stock-rises-550-percent-in-1-year\/#Why_did_the_Cupid_share_price_rise_so_much\" title=\"Why did the Cupid share price rise so much?\">Why did the Cupid share price rise so much?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/multibagger-healthcare-stock-rises-550-percent-in-1-year\/#Did_the_Cupid_bonus_issue_affect_the_1-year_return\" title=\"Did the Cupid bonus issue affect the 1-year return?\">Did the Cupid bonus issue affect the 1-year return?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/multibagger-healthcare-stock-rises-550-percent-in-1-year\/#What_were_Cupid_Q1_FY27_results\" title=\"What were Cupid Q1 FY27 results?\">What were Cupid Q1 FY27 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/multibagger-healthcare-stock-rises-550-percent-in-1-year\/#What_is_the_52-week_high_and_low_of_Cupid\" title=\"What is the 52-week high and low of Cupid?\">What is the 52-week high and low of Cupid?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/multibagger-healthcare-stock-rises-550-percent-in-1-year\/#Is_this_multibagger_healthcare_stock_overvalued\" title=\"Is this multibagger healthcare stock overvalued?\">Is this multibagger healthcare stock overvalued?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/multibagger-healthcare-stock-rises-550-percent-in-1-year\/#What_is_the_Cupid_share_price_target\" title=\"What is the Cupid share price target?\">What is the Cupid share price target?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/multibagger-healthcare-stock-rises-550-percent-in-1-year\/#Should_I_buy_a_multibagger_healthcare_stock_after_a_550_rally\" title=\"Should I buy a multibagger healthcare stock after a 550% rally?\">Should I buy a multibagger healthcare stock after a 550% rally?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Which_Multibagger_Healthcare_Stock_Rose_550_in_1_Year\"><\/span><strong>Which Multibagger Healthcare Stock Rose 550% in 1 Year?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The answer is Cupid. The multibagger healthcare stock climbed from a bonus-adjusted level of roughly Rs 43 a year ago to around Rs 281 today. It touched a record high of Rs 299 in August 2026, while its 52-week low stands at Rs 37.46.<\/p>\n<p>The table below shows how the stock has performed across periods and where it ranks among the 101 stocks in our screen. All figures are adjusted for corporate actions.<\/p>\n<table>\n<thead>\n<tr>\n<th>Period<\/th>\n<th>Return<\/th>\n<th>Rank (out of 101)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1 Month<\/td>\n<td>0.21%<\/td>\n<td>95<\/td>\n<\/tr>\n<tr>\n<td>6 Months<\/td>\n<td>227.82%<\/td>\n<td>3<\/td>\n<\/tr>\n<tr>\n<td>1 Year<\/td>\n<td>550.05%<\/td>\n<td>2<\/td>\n<\/tr>\n<tr>\n<td>3 Years<\/td>\n<td>6,701.93%<\/td>\n<td>1<\/td>\n<\/tr>\n<tr>\n<td>5 Years<\/td>\n<td>12,196.94%<\/td>\n<td>1<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The 1-month number shows the rally has paused. The stock has been consolidating between Rs 265 and Rs 300 since mid-August, after a near straight-line run from April to August 2026. Few names in our screen match this multibagger healthcare stock on consistency, with a top-three rank in the 6-month, 1-year, 3-year and 5-year windows.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Is_the_550_Rise_Real_or_a_Bonus_Share_Effect\"><\/span><strong>Is the 550% Rise Real or a Bonus Share Effect?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The rise is real price appreciation. Cupid issued 4:1 bonus shares with a record date of 9 March 2026, so the unadjusted price fell from above Rs 400 to around Rs 80 on the ex-date. Our return figures compare bonus-adjusted prices, so the bonus does not inflate them.<\/p>\n<p>The company also split its shares from a face value of Rs 10 to Re 1 and issued 1:1 bonus shares in April 2024. These actions explain why the 3-year and 5-year returns look extreme. Even after full adjustment, the multibagger healthcare stock has multiplied roughly 68 times in three years, a sign of a real business re-rating rather than an accounting quirk. For anyone comparing the multibagger healthcare stock with peers, adjusted prices are the fair yardstick.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Did_This_Multibagger_Healthcare_Stock_Rise_550\"><\/span><strong>Why Did This Multibagger Healthcare Stock Rise 550%?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Four forces drove the rally: rapid earnings growth, repeated upgrades to management guidance, new capacity and a push into consumer products. Each one fed the next, and the market rewarded the multibagger healthcare stock with a steep rise in valuation.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"1_Profits_Nearly_Tripled_in_a_Year\"><\/span><strong>1. Profits Nearly Tripled in a Year<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Cupid posted Q1 FY27 revenue of Rs 156.99 crore, up about 142% from Rs 64.74 crore a year earlier. Net profit rose approximately 194% to Rs 44.15 crore from Rs 15.01 crore. For the full year FY26, revenue almost doubled to Rs 391.40 crore and net profit jumped to Rs 108.23 crore from Rs 40.89 crore.<\/p>\n<p>Revenue has now grown for five straight quarters. This consistency matters because it shows the multibagger healthcare stock is not riding on a single large order. That earnings trajectory is the core reason the multibagger healthcare stock re-rated so quickly.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_Guidance_Raised_Again_and_Again\"><\/span><strong>2. Guidance Raised Again and Again<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Management first guided for FY26 revenue of about Rs 335 crore and delivered Rs 391.40 crore. In July 2026, it lifted the FY27 revenue target from Rs 600 crore to more than Rs 660 crore. After the Q1 results in August, it raised the goal again to Rs 725 crore to Rs 750 crore, with net profit guidance of Rs 210 crore to Rs 225 crore.<\/p>\n<p>Each upgrade triggered a fresh leg higher in the Cupid share price. Investors now track the company&#8217;s longer-term aim of around Rs 1,500 crore in revenue by FY29. For a multibagger healthcare stock, guidance that is beaten rather than missed builds trust quickly.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_Global_Tender_Wins_and_Export_Price_Hikes\"><\/span><strong>3. Global Tender Wins and Export Price Hikes<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Cupid is prequalified by the WHO and UNFPA for both male and female condoms, which makes it eligible for large public health tenders. It received an allocation under a South African condom programme in November 2025 and signed a long-term supply agreement with a Netherlands-based global health supply chain body.<\/p>\n<p>Exports made up approximately 59% of FY26 revenue, with products sold in more than 125 countries. The company also pushed through a minimum 10% price increase across its export portfolio, which supports margins. Tender visibility gives the multibagger healthcare stock a steady institutional revenue base alongside its consumer brands.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"4_New_Capacity_and_a_Consumer_Products_Push\"><\/span><strong>4. New Capacity and a Consumer Products Push<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>A new facility at Palava is expected to take annual capacity to about 1.25 billion male condoms and 125 million female condoms, with commissioning planned in Q2 FY27. The board has also approved plans for a manufacturing venture in South Africa and an FMCG unit in Saudi Arabia.<\/p>\n<p>On the consumer side, the Consumer Healthcare and FMCG portfolio contributed Rs 121.61 crore in FY26, including Rs 84.26 crore from newly launched products. This diversification gives the multibagger healthcare stock a second growth engine beyond institutional tenders.<\/p>\n<p style=\"margin-top:24px;\"><strong>Check the Univest Screener for Live Fundamentals of High-Return Stocks<\/strong><\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_Does_This_Multibagger_Healthcare_Stock_Compare_With_Its_Sector\"><\/span><strong>How Does This Multibagger Healthcare Stock Compare With Its Sector?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Cupid operates in a niche corner of healthcare. The global market for public health condom supply is served by a small group of WHO-prequalified manufacturers, and Cupid is one of the few that is approved for both male and female condoms. That qualification is hard to win and takes years to build.<\/p>\n<p>The company also says it is the only Indian manufacturer with dedicated natural latex and premium nitrile production lines. This gives the multibagger healthcare stock an edge in premium and specialised products that carry better pricing.<\/p>\n<p>The contrast with the wider sector shows up in valuation. The industry PE is approximately 35.58, while Cupid trades at more than seven times that level. The market is treating the multibagger healthcare stock as a high-growth consumer and export story rather than a traditional contract manufacturer, and that view will be tested with every quarterly result.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Financial_Performance_of_the_Multibagger_Healthcare_Stock\"><\/span><strong>Financial Performance of the Multibagger Healthcare Stock<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Margins have widened alongside revenue. The operating margin rose from 35.82% in Q1 FY26 to 40.29% in Q1 FY27, and the full-year FY26 operating margin reached 42.06% against 33.45% in FY25.<\/p>\n<table>\n<thead>\n<tr>\n<th>Quarter<\/th>\n<th>Revenue (Rs Cr)<\/th>\n<th>EBITDA (Rs Cr)<\/th>\n<th>Net Profit (Rs Cr)<\/th>\n<th>Operating Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Jun 2025<\/td>\n<td>64.74<\/td>\n<td>21.41<\/td>\n<td>15.01<\/td>\n<td>35.82%<\/td>\n<\/tr>\n<tr>\n<td>Sep 2025<\/td>\n<td>90.23<\/td>\n<td>34.19<\/td>\n<td>24.13<\/td>\n<td>40.50%<\/td>\n<\/tr>\n<tr>\n<td>Dec 2025<\/td>\n<td>104.39<\/td>\n<td>45.19<\/td>\n<td>32.83<\/td>\n<td>48.33%<\/td>\n<\/tr>\n<tr>\n<td>Mar 2026<\/td>\n<td>132.04<\/td>\n<td>49.59<\/td>\n<td>36.26<\/td>\n<td>41.35%<\/td>\n<\/tr>\n<tr>\n<td>Jun 2026<\/td>\n<td>156.99<\/td>\n<td>62.32<\/td>\n<td>44.15<\/td>\n<td>40.29%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The balance sheet is clean. Debt to equity stands at approximately 0.13, and return on equity is about 24%. Operating cash flow turned positive at Rs 46.12 crore in FY26 after a negative Rs 11.14 crore in FY25. A multibagger healthcare stock with rising margins and little debt is rarer than one with rising sales alone.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Who_Owns_This_Multibagger_Healthcare_Stock\"><\/span><strong>Who Owns This Multibagger Healthcare Stock?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Promoters have steadily raised their stake, while foreign investors have started to show up. Domestic institutions still hold very little, which means the shareholder base is dominated by retail and non-institutional investors.<\/p>\n<table>\n<thead>\n<tr>\n<th>Quarter<\/th>\n<th>Promoters<\/th>\n<th>FII<\/th>\n<th>DII<\/th>\n<th>Public<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Jun 2025<\/td>\n<td>42.52%<\/td>\n<td>0.95%<\/td>\n<td>0.11%<\/td>\n<td>56.43%<\/td>\n<\/tr>\n<tr>\n<td>Sep 2025<\/td>\n<td>45.55%<\/td>\n<td>2.58%<\/td>\n<td>0.34%<\/td>\n<td>51.52%<\/td>\n<\/tr>\n<tr>\n<td>Dec 2025<\/td>\n<td>45.55%<\/td>\n<td>1.48%<\/td>\n<td>0.30%<\/td>\n<td>52.67%<\/td>\n<\/tr>\n<tr>\n<td>Mar 2026<\/td>\n<td>46.03%<\/td>\n<td>1.01%<\/td>\n<td>0.17%<\/td>\n<td>52.79%<\/td>\n<\/tr>\n<tr>\n<td>Jun 2026<\/td>\n<td>46.24%<\/td>\n<td>4.17%<\/td>\n<td>0.34%<\/td>\n<td>49.25%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>FII holding jumped to 4.17% in June 2026 from 1.01% in March. Promoters also cut pledged shares from 36.13% in September 2025 to 20% by December 2025, a move that reassured investors. In July 2026, the stock moved into the BSE Group A category. Rising FII interest suggests the multibagger healthcare stock is starting to appear on global investor radars.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_Before_Buying_This_Multibagger_Healthcare_Stock\"><\/span><strong>Key Risks Before Buying This Multibagger Healthcare Stock<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The biggest risk is valuation. The stock trades at a PE of approximately 274 against an industry PE of around 35.58, and a price to book ratio near 83. Even strong earnings growth may not keep pace with such a premium if sentiment turns. A multibagger healthcare stock trading at this multiple can fall sharply on a single weak quarter.<\/p>\n<p>Second, the business depends heavily on institutional tenders from global health agencies and governments. Tender allocations can be lumpy, and any cut in donor funding for public health programmes could hurt order flow for the multibagger healthcare stock.<\/p>\n<p>Third, volatility is extreme. The Cupid share price fell from Rs 105.39 to about Rs 68 in early January 2026 before recovering, and it slipped about 21% intraday in August 2026 from the Rs 299 peak. Low institutional ownership can make such swings sharper.<\/p>\n<p>Finally, execution of the new Palava capacity and overseas ventures must go to plan. Delays or cost overruns could force the company to miss its raised guidance, which is already built into the multibagger healthcare stock&#8217;s price.<\/p>\n<p style=\"margin-top:24px;\"><strong>Download the <a href=\"https:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track the Cupid share price live<\/strong><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Cupid_Share_Analyst_View\"><\/span><strong>Cupid Share: Analyst View<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Market experts broadly agree that the business momentum is strong but caution that the price has run far ahead of fundamentals. In January 2026, technical analysts described the Cupid share as overbought and suggested partial profit booking with a trailing stop loss.<\/p>\n<p>Since then, the company has beaten expectations again and the Cupid share price has more than tripled from its post-bonus levels. Analysts note that the multibagger healthcare stock still has limited formal research coverage, which can widen price swings. The stock now trades just around 6% below its record high.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Cupid_Share_Price_Target\"><\/span><strong>Cupid Share Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>No verified brokerage Cupid share price target is currently available, as the stock has limited formal research coverage. Investors should treat unverified online forecasts with caution.<\/p>\n<p>Without a verified Cupid share price target, key price levels offer a better guide. The record high of Rs 299 acts as near-term resistance, while the Rs 265 zone, where the stock found buyers in August and September, is the nearest support.<\/p>\n<p>Management guidance is the other reference point. If Cupid delivers FY27 net profit of Rs 210 crore to Rs 225 crore, the forward PE would fall to roughly 167 to 179 at the current market value, still well above sector averages. Any fresh Cupid share price target from a brokerage will likely hinge on this execution.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>This multibagger healthcare stock has earned its 550% gain through real numbers: profits nearly tripled, guidance was raised repeatedly and new capacity is on the way. The 4:1 bonus in March 2026 did not distort the return, since the figures are adjusted.<\/p>\n<p>The flip side is a valuation that leaves little room for error. Investors tracking the Cupid share price should watch Q2 FY27 results, Palava commissioning and tender flows, and consider staggered entries rather than chasing the multibagger healthcare stock at record levels.<\/p>\n<p>Over the next few quarters, the multibagger healthcare stock will be judged less on its past return and more on whether it can hit Rs 725 crore to Rs 750 crore in revenue this year.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information and may or may not be accurate. Please verify all data independently before making any investment decision. Past returns do not guarantee future returns. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Which_multibagger_healthcare_stock_rose_550_in_1_year\"><\/span><strong>Which multibagger healthcare stock rose 550% in 1 year?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Cupid Ltd (NSE: CUPID) is the multibagger healthcare stock that gained approximately 550.05% over one year as of 10 September 2026. It ranked second among 101 NSE stocks in our screen for 1-year returns.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_did_the_Cupid_share_price_rise_so_much\"><\/span><strong>Why did the Cupid share price rise so much?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Cupid share price rose on sharp profit growth, which made it a standout multibagger healthcare stock,, repeated guidance upgrades and new capacity. Q1 FY27 net profit jumped about 194% to Rs 44.15 crore, and FY27 revenue guidance was raised to Rs 725 crore to Rs 750 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Did_the_Cupid_bonus_issue_affect_the_1-year_return\"><\/span><strong>Did the Cupid bonus issue affect the 1-year return?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. Cupid issued 4:1 bonus shares with a record date of 9 March 2026, but the 550% return is calculated on bonus-adjusted prices. The gain reflects real price appreciation.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_Cupid_Q1_FY27_results\"><\/span><strong>What were Cupid Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Cupid reported Q1 FY27 revenue of Rs 156.99 crore, up about 142% year on year, and net profit of Rs 44.15 crore, up about 194%. The operating margin of the multibagger healthcare stock stood at 40.29%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_52-week_high_and_low_of_Cupid\"><\/span><strong>What is the 52-week high and low of Cupid?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Cupid has a 52-week high of Rs 299, hit in August 2026, and a 52-week low of Rs 37.46. The multibagger healthcare stock traded around Rs 281.40 on 10 September 2026.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_multibagger_healthcare_stock_overvalued\"><\/span><strong>Is this multibagger healthcare stock overvalued?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> On trailing numbers, yes. The stock trades at a PE of approximately 274 against an industry PE of about 35.58, so investors are pricing in several years of strong growth.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Cupid_share_price_target\"><\/span><strong>What is the Cupid share price target?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> There is no verified brokerage target at present. Investors can track the Rs 299 record high as resistance and the Rs 265 zone as near-term support.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Should_I_buy_a_multibagger_healthcare_stock_after_a_550_rally\"><\/span><strong>Should I buy a multibagger healthcare stock after a 550% rally?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> After a 550% move, much of the good news is already in the price, so risk is higher for fresh buyers of this multibagger healthcare stock. Staggered buying, a clear stop loss and advice from a SEBI-registered advisor are sensible steps.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"Which multibagger healthcare stock rose 550% in 1 year?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Cupid Ltd (NSE: CUPID) is the multibagger healthcare stock that gained approximately 550.05% over one year as of 10 September 2026. It ranked second among 101 NSE stocks in our screen for 1-year returns.\"}},{\"@type\":\"Question\",\"name\":\"Why did the Cupid share price rise so much?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Cupid share price rose on sharp profit growth, which made it a standout multibagger healthcare stock,, repeated guidance upgrades and new capacity. Q1 FY27 net profit jumped about 194% to Rs 44.15 crore, and FY27 revenue guidance was raised to Rs 725 crore to Rs 750 crore.\"}},{\"@type\":\"Question\",\"name\":\"Did the Cupid bonus issue affect the 1-year return?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. Cupid issued 4:1 bonus shares with a record date of 9 March 2026, but the 550% return is calculated on bonus-adjusted prices. The gain reflects real price appreciation.\"}},{\"@type\":\"Question\",\"name\":\"What were Cupid Q1 FY27 results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Cupid reported Q1 FY27 revenue of Rs 156.99 crore, up about 142% year on year, and net profit of Rs 44.15 crore, up about 194%. The operating margin of the multibagger healthcare stock stood at 40.29%.\"}},{\"@type\":\"Question\",\"name\":\"What is the 52-week high and low of Cupid?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Cupid has a 52-week high of Rs 299, hit in August 2026, and a 52-week low of Rs 37.46. The multibagger healthcare stock traded around Rs 281.40 on 10 September 2026.\"}},{\"@type\":\"Question\",\"name\":\"Is this multibagger healthcare stock overvalued?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"On trailing numbers, yes. The stock trades at a PE of approximately 274 against an industry PE of about 35.58, so investors are pricing in several years of strong growth.\"}},{\"@type\":\"Question\",\"name\":\"What is the Cupid share price target?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"There is no verified brokerage target at present. Investors can track the Rs 299 record high as resistance and the Rs 265 zone as near-term support.\"}},{\"@type\":\"Question\",\"name\":\"Should I buy a multibagger healthcare stock after a 550% rally?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"After a 550% move, much of the good news is already in the price, so risk is higher for fresh buyers of this multibagger healthcare stock. Staggered buying, a clear stop loss and advice from a SEBI-registered advisor are sensible steps.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>A contraceptive and sexual wellness maker turned Rs 1 lakh into about Rs 6.5 lakh in a year. Here is what drove the 550% rally and the risks to weigh.<\/p>\n","protected":false},"author":29,"featured_media":240798,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[],"class_list":["post-240800","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["240798"],"rank_math_title":["Multibagger Healthcare Stock Up 550% in 1 Year: Why It Rallied"],"rank_math_description":["This multibagger healthcare stock rose approximately 550% in 1 year on tripled profits, raised guidance and new capacity. See financials, key risks and levels to watch."],"rank_math_focus_keyword":["multibagger healthcare stock"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/09\/multibagger-healthcare-stock-rises-550-percent-in-1-year.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/240800","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=240800"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/240800\/revisions"}],"predecessor-version":[{"id":240802,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/240800\/revisions\/240802"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/240798"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=240800"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=240800"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=240800"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}